Lionnel Geoffrois, Alexandre Harlé, Nassim Sahki, Aleksandra Sikanja, Florence Granel-Brocard, Alice Hervieu, Laurent Mortier, Géraldine Jeudy, Catherine Michel, Charlée Nardin, Cécile Huin-Schohn, Jean-Louis Merlin
BACKGROUND: With more than 15,000 new cases /year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or resectable metastatic (stage IV) melanomas, medical adjuvant treatment is proposed and recent advances had shown the benefit of anti-PD1/PDL1 and anti-CTLA4 immunotherapy as well as anti-BRAF and anti-MEK targeted therapy in BRAF V600 mutated tumors. However, the recurence rate at one year is approximately 30% and justify extensive research of predictive biomarkers...
June 16, 2023: BMC Cancer